CompoAtlas

Healthy Fertility (Women's)

Healthy Fertility (Women's), NPN 80090943: natural health product licensed in Canada. Medicinal ingredients: Riboflavine, Camellia sinensis, Vitamine E, Ubiquinol.

If this product were sold in France

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and sourcePer dosage unit, according to the sourceMaximum per day, adult
Riboflavine

Source : Riboflavine

1 milligramme3,000 µg
Camellia sinensis

Source : Feuille

Extract : Matériel brut sec

Extraction ratio : 30:1

Dry plant equivalent : 3,000 milligramme

Potency : 2 % Caffeine

100 milligrammeNot calculated
Vitamine E

Source : d-alpha tocophérol

100 Unités internationalesNot calculated
Vitamine E

Source : d-alpha tocophérol

67.11 mg ATNot calculated
Ubiquinol

Source : Ubiquinol

100 milligrammeNot calculated
Vitamine B6

Source : Pyridoxal 5'-phosphate

2 milligramme6,000 µg
Zinc

Source : Citrate de zinc

3.5 milligramme10,500 µg
Folate

Source : Acide folique

0.133 milligrammeNot calculated
Fer

Source : Citrate de fer (II)

6 milligramme18,000 µg
L-arginine

Source : Anas falcata - plume

233 milligrammeNot calculated
Camellia sinensis

Source : Feuille

Potency : 50 % (-)-Epicatechin

Not specifiedNot calculated

Non-medicinal ingredients

Hypromellose

PopulationAgeQuantity per servingFrequency
Adultes de sexe fémininNot specified1 Capsule3 days

Uses authorised in Canada

Source of antioxidant(s) / Provides antioxidant(s) that help(s) fight/protect 9cell) against/reduce (the oxidative effect of/the oxidative damage caused by cell damage caused by ) free radicals. Helps to reduce the risk of neural tube defects when taken daily at least three months prior to becoming pregnant and during early pregnancy. Helps to support normal early development of the fetal brain and spinal cord. Used in Herbal Medicine to help relieve premenstrual symptoms. Used in Herbal Medicine as a hormone normaliser to help stabilise menstrual cycle irregularities. Used in Herbal Medicine to help relieve symptoms associated with menopause, such as hot flushes.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

Product record

Licence holder
Luvolux Inc.
NPN or DIN-HM
80090943
Status
Inactive licence
Licence date
25 February 2019
Revision date
Not provided
Form
Capsule
Route of administration
Orale
Application type
Non traditionnelle

Source

Official Health Canada record, licence 80090943

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Ubiquinol
    Read the warning, when it applies and the studies cited

    UBIQUINOL

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Langsjoen and Langsjoen 2008; Rosenfeldt et al. 2007; Engelsen et al. 2003; Singh et al. 1999; Landbo and Almdal 1998; Spigset 1994).

    Sources cited by Health Canada (6)
    • Engelsen J, Nielsen JD, Hansen KF. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
    • Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
    • Langsjoen PH, Langsjoen AM. Supplemental ubiquinol in patients with advanced congestive heart failure. Biofactors 2008;32(1-4):119-128. PubMed Clinical trial
    • Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
    • Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial
    • Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report

    Applies to products providing more than 100 mg of Ubiquinol, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Langsjoen and Langsjoen 2008; Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).

    Sources cited by Health Canada (4)
    • Engelsen J, Nielsen JD, Hansen KF. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
    • Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
    • Langsjoen PH, Langsjoen AM. Supplemental ubiquinol in patients with advanced congestive heart failure. Biofactors 2008;32(1-4):119-128. PubMed Clinical trial
    • Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report

    Condition of application: Migraine prophylaxis/prevention.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.

    Health Canada monograph dated 30 January 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Healthy Fertility (Women's) (Luvolux Inc.): composition and ingredients”, https://compoatlas.com/en/supplements/canada/80090943-healthy-fertility-women-s, updated 25 February 2019.

Enter to analyse, Shift+Enter for a new line